Eurocine Vaccines AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private, Subsidiary
- Employees
- 3
- Market Cap
- -
Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: PlaceboBiological: Immunose™ FLU 2%, 300 μlBiological: Immunose™ FLU 2%, 200 μlBiological: Immunose™ FLU 1%Biological: Influenza antigenBiological: i.m comparator
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Eurocine Vaccines AB
- Target Recruit Count
- 298
- Registration Number
- NCT03437304
- Locations
- 🇸🇪
Site 5, Borås, Sweden
🇸🇪Site 4, Helsingborg, Sweden
🇸🇪Site 2, Linköping, Sweden
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
Phase 1
Completed
- Conditions
- Influenza, Human
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Eurocine Vaccines AB
- Target Recruit Count
- 162
- Registration Number
- NCT02998996
- Locations
- 🇸🇪
Site 2, Linkoping, Sweden
🇸🇪Site 1, Uppsala, Sweden
News
No news found